Reporting to president and CEO
"We received a lot of interest in the CFO position and met with many impressive candidates," said
"After meeting with Randal and the team, I was thoroughly impressed with everyone's drive and sense of purpose to develop breakthrough vaccines," remarked
Prior to joining IVT,
ImmunoVaccine Technologies is a vaccine development company focused on the commercialization of its novel vaccine candidates. IVT continues to strengthen its vaccine pipeline through licensing and strategic partnering to develop therapeutic cancer and infectious disease vaccines. www.immunovaccine.com
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future are forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. IVT assumes no responsibility to update forward-looking statements in this press release.
For further information: Jennifer Ayotte, Communications, (902) 209-4704, [email protected]
Share this article